Price when posted : NSE: Rs. 161.95

The following email was sent by me to the SPARC management. Othe retail investors may think of doing the same:Sir/s Yet another quarter in massive red ink. It is over 12 years now SPARC was listed. What the retail investor who relied on the Sun Pharma brand got for his faith: NO DIVIDENDS FOR 12 LONG YEARS. NO CAPITAL APPRECIATION. INSTEAD LOSSES WITH EVERY QUARTER RESULT. Investors understand pharma research is risky, but managements must have some concern for their investors………….. this is morally and ethically as sound expectation. Failures of the Management: Inadequate and slow responses when it comes to commercialising successful molecules. In spite of increase in authorised Share capital , NO NEWS IN A RIGHTS ISSUE WHICH WILL BE DISCOUNTED FOR THE BENEFIT OF RETAIL INVESTORS. Despite assurances of promise……………. NO POSITIVE PROGRESS ON TACLANTIS APPROVAL BY FDA. Successes so far: KEY MOLECULES AT INFLEXION POINTS- BUT WHEN WILL THEY EARN MONEY ON THEIR OWN. KINDLY HAVE SOME CONCERN FOR THE INVESTORS WHO HAVE PUT THEIR MONEY FOR SO LONG AND: QUICKLY COME UP WITH A ATTRACTIVE RIGHTS ISSUE OR COMMERCIALISE A MOLECULE OR GE TACLANTIS APPROVAL DONE EXPEDITIOUSLY OR GO FOR A REVERSE MERGER BY MERGING SPARC WITH SUN PHARMA. A RETAIL INVESTOR IN SPARC SINCE 2008

Why is the message offensive? Please click on the reason below to notify the moderating team. Marking good messages offensive will put you on the moderating team`s radar.

Repost this message

The following email was sent by me to the SPARC management. Othe retail investors may think of doing the same:Sir/s Yet another quarter in massive red ink. It is over 12 years now SPARC was listed. What the retail investor who relied on the…&nbsp

Thank you for reposting this message.





Source link
#opinion #news #Post #comment

Leave a comment

Your email address will not be published. Required fields are marked *